Investor Overview

PTI (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.51 (3.81%)
Data as of 10/25/16 2:42 p.m. ET
Corporate Profile

Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Our initial therapeutic focus is on cystic fibrosis, or CF, which is caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. ... More >>

Recent NewsMore >>
Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Board
September 28, 2016
Read More

Proteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Conference
September 22, 2016
Read More

Proteostasis Therapeutics to Present at Upcoming Investor Conferences
September 15, 2016
Read More

Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.